The following is a summary of top news stories Tuesday.
———-
COMPANIES
———-
Consumer healthcare firm Haleon, in its first earnings report since being split from pharmaceutical maker GSK and separately listed, reported a strong performance in the first half of 2022, noting double-digit revenue growth during the period. For the six months that ended on June 30, Haleon reported a pretax profit of £864 million, up 17% from £736 million a year ago, as operating profit increased by 22% to £900 million from £737 million. Revenue grew 13% to £5.19 billion from £4.58 billion. In Oral Health, Haleon said revenue grew 5.1% to £1.44 billion from £1.36 billion a year earlier, maintaining its ‘track record of market outperformance’. Whilst noting current macro-economic challenges and uncertainties, Haleon said the positive momentum seen in the first half has continued into the second half of the year. Haleon said it is confident it is well positioned to deliver on guidance this year. Full-year revenue growth is expected between 6% and 8%.
———-
AstraZeneca said…
